Real-World Impact of Switching From Insulin Glargine (Lantus ® ) to Basaglar ® and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia.
Frontiers in public health（2022）
Abstract
Basaglar and potentially other biosimilar insulin glargine products can lead to significant cost savings without compromising the quality of care. However, their acquisition prices should be discounted.
MoreTranslated text
Key words
Basaglar®,Lantus®,Saudi Arabia,cost savings,diabetes mellitus,insulin glargine
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined